The Food and Drug Administration (FDA) has produced a large number of extremely useful guidances for industry. These guidances include recommendations about the development, review, and approval of various disease-specific drugs, as well as general matters related to drug metabolism/drug interactions, premarketing risk assessment, pharmacogenetics, and pharmacovigilance. In May 2008, the FDA held a public workshop to aid in the development of a draft guidance about how to use large electronic health care databases for drug safety studies.1 The draft guidance, which will be completed in fiscal year 2010 and finalized in 2011, aims ambitiously at being a major part of a national strategy to monitor medical product safety.2
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.